UK Reviewing Weight Loss Drug Data

I'm not sure where to put this on the forum. But I've been musing about why PF hasn't bought recently. Yes, I know he follows no discernible pattern. But, given both the recent FDA approval, after 18 months in limbo, and the 10% drop in one day, I resorted to conjuring and fantasizing. Then I seemed to recall a recent CNBC interview with the CEO, in which I THINK he was asked about the absence of a weight loss asset in the company portfolio. Then I remembered PF talking during the R&D Day about back burner assets/projects that we may be hearing more about in the near future. Finally, a few minutes ago I saw the news below hit the tape, so the weight loss story continues to unfold in interesting ways.

UK Reviews Weight-Loss Drug Data Over Suicide Risk, Reuters Says
2023-07-26 13:12:30.663 GMT


By Kevin Simauchi
(Bloomberg) -- The UK’s Medicines and Healthcare products
Regulatory Agency is reviewing weight-loss treatments, including
Novo Nordisk’s Ozempic and Saxenda, after some patients reported
suicidal thoughts, Reuters reports, citing the watchdog.
* Sanofi’s lixisenatide, Eli Lilly’s dulaglutide, and
AstraZeneca’s exenatide are also included in MHRA review
* Novo Nordisk told Reuters that it got a request from MHRA
regarding the review and it will provide a response “within the
requested timelines”
** Sanofi, Eli Lilly, AstraZeneca didn’t immediately respond to
Reuters’s requests for comment
* NOTE: July 12, EU Widens Probe of Suicide Risks Linked to
Weight-Loss Drugs